US demands new Phase III trial for Targanta's oritavancin
This article was originally published in Scrip
Executive Summary
The US FDAis requiring an additional Phase III study before it will approveTarganta Therapeutics' antibiotic Nuvocid (oritavancin) for complicated skin and skin structure infections (cSSSI), the company said.